ketorolac ophthalmic / Generic mfg. - LARVOL DELTA

Granulomatous Rosacea with Ocular Involvement: A Case Masquerading as Herpes Zoster Ophthalmicus (EADV 2025) - "An ophthalmologist prescribed ocular ketorolac for suspected keratitis...He had nodulocystic acne four years earlier, with good response to oral isotretinoin...Prednisone 40 mg/day for five days, acyclovir 800 mg five times daily for seven days, and intensive skin hydration were started...In such cases, 1% topical ivermectin is advised, and combination therapy may be required for resistant cases... ** This case highlights the need for accurate differential diagnosis and proper management of rosacea with ocular signs. Early intervention is critical when serious conditions like herpes zoster ophthalmicus are suspected. Antivirals with corticosteroids offered effective initial control, preventing complications."

Clinical • Acne Vulgaris • Atopic Dermatitis • Dermatology • Herpes Zoster • Immunology • Keratitis • Ocular Inflammation • Ophthalmology • Pruritus • Rosacea • Varicella Zoster

Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy. (PubMed, J Vitreoretin Dis) - "Compared with untreated groups, the frequency of CME regression was not influenced by the administration of sub-Tenon triamcinolone acetonide (75.0% vs 75.0%; P = 1.00), prednisolone acetate eyedrops (75.0% vs 75.0%; P = 1.00), or ketorolac eyedrops (71.4% vs 76.9%; P = .79). The viscosity of the SO used for vitreous tamponade in RD repair may play a role in the development of CME, with lighter grade oil increasing the risk for disease. Furthermore, SO removal alone potentially leads to a prominent reduction in CME in most cases."

Journal • Macular Edema • Ophthalmology • Retinal Disorders

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparing the sedative and analgesic effects of ketorolac and diclofenac eye drops among patients with cataract surgery: A double-blind randomized clinical trial. (PubMed, Oman J Ophthalmol) - "Ketorolac eye drops are more effective than diclofenac eye drops in significantly reducing intraoperative pain among the candidates for CS with topical anesthesia. Therefore, ketorolac eye drops can be used with tetracaine eye drops in CS with topical anesthesia to produce greater perioperative analgesia and sedation."

Clinical • Journal • Surgery • Anesthesia • Cataract • Ophthalmology • Pain

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (clinicaltrials.gov) - P2 | N=82 | Terminated | Sponsor: Emory University | Phase classification: P1 ➔ P2 | Trial completion date: Oct 2024 ➔ Feb 2024 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2024 ➔ Feb 2024; This study was terminated after interim analyses showed no benefits.

Biomarker • Phase classification • Surgery • Trial completion date • Trial primary completion date • Trial termination • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Nsaid-Induced Corneal Melt As The First Presentation Of Sjögren'S Syndrome Following An Uncomplicated Cataract Surgery (ESCRS 2024) - "Post-operative treatment included G. Acular (Ketorolac Tromethamine 0.5%, NSAID: non-steroidal anti-inflammatory drug) and G. Tobradex (Tobramycin 0.3% and Dexamethasone 0.1%, antibiotic and steroid respectively) each prescribed four times a day for two weeks. 4. The prescription of preservative-free eye drops is recommended, and topical NSAIDs should be prescribed judiciously or even avoided in patients with compromised ocular surfaces, considering the risk of corneal melt."

Surgery • Achromatopsia • Cataract • Dry Eye Disease • Macular Edema • Ophthalmology

INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (clinicaltrials.gov) - P1 | N=164 | Active, not recruiting | Sponsor: Stephen J. Kim, MD | N=264 ➔ 164

Enrollment change • Diabetic Retinopathy • Retinal Disorders • CXCL8 • IL6 • VEGFA

CES-NSLT: Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (clinicaltrials.gov) - P4 | N=126 | Not yet recruiting | Sponsor: St. Joseph's Healthcare Hamilton

New P4 trial • Cardiovascular • Glaucoma • Inflammation • Ophthalmology

NSAID-induced corneal melt as the first presentation of Sjögren's syndrome. (PubMed, BMJ Case Rep) - "Postoperative treatment included G. Acular (Ketorolac Tromethamine 0.5%, NSAID: non-steroidal anti-inflammatory drug) and G. Tobradex (Tobramycin 0.3% and Dexamethasone 0.1%, antibiotic and steroid, respectively) each prescribed four times a day for 2 weeks. On investigation, the patient had positive anti-RO and anti-LA antibodies, suggesting a diagnosis of Sjögren's syndrome. We advocate for careful preoperative assessment prior to cataract surgery, patient education, close follow-up and cautious medication use postoperatively including avoiding NSAID drops in patients with risk factors for postoperative dry eye disease."

Journal • Achromatopsia • Cataract • Dry Eye Disease • Immunology • Ophthalmology • Rheumatology • Sjogren's Syndrome • Transplantation

INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (clinicaltrials.gov) - P1 | N=264 | Active, not recruiting | Sponsor: Stephen J. Kim, MD | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Retinopathy • Retinal Disorders • CXCL8 • IL6 • VEGFA

Neurotrophic Keratopathy after wide retinal endolaser and postoperative Ketorolac eye drops: A case series. (PubMed, Eur J Ophthalmol) - "Postoperative Ketorolac eye drops, in patients who underwent PPV with endolaser, may reduce the corneal sensitivity, predispose to epithelial disruption and NK development. Studies are needed to explore the effect of NSAIDs on corneal sensitivity reduction in patient who will undergo PPV and extensive endolaser."

Journal • Diabetes • Dry Eye Disease • Keratitis • Metabolic Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Preparation of Polycaprolactone and Polymethacrylate Nanofibers for Controlled Ocular Delivery of Ketorolac tromethamine: Pharmacokinetic study in Rabbit's Eye. (PubMed, Eur J Pharm Sci) - "Acceptable cell viability confirmed the safety of inserts. Due to the fact that this preservative-free polymer insert can obtain therapeutic concentration in the tear film without fluctuation, it can be a suitable alternative for the treatment of intraocular inflammations with less complications, easier use, and even higher intraocular penetration."

Journal • PK/PD data • Preclinical • Allergy • Immunology • Inflammation • Ocular Inflammation • Ophthalmology

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Sep 2023 ➔ Oct 2024 | Trial primary completion date: Sep 2023 ➔ Oct 2024

Biomarker • Surgery • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA

Preformulation-Assisted Design of Ketorolac Tromethamine for Effective Ophthalmic Delivery. (PubMed, J Ocul Pharmacol Ther) - "Being a weak ionizable drug, both water and lipid solubility, as measured through partition coefficients, it demonstrated pH-dependency. For the optimum balance of water and lipid solubility required for penetration through the lipophilic corneal epithelial barrier, ketorolac eye drops would be better formulated between pH 5.5 and 6.6 than being formulated at the physiological fluid pH 7.4, where the drug is extremely hydrophilic and less permeable."

Journal • Conjunctivitis • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain

Formulation and In-Vitro/Ex-Vivo Characterization of Pregelled Hybrid Alginate-Chitosan Microparticles for Ocular Delivery of Ketorolac Tromethamine. (PubMed, Polymers (Basel)) - "Conclusively, the cytotoxicity assay confirmed that the investigated MPs were non-irritant and could confer protection from direct drug irritation of KT on the ocular surface. The MTT cytotoxicity assay confirmed that KT-loaded MPs showed acceptable and reasonable tolerability with both human lens and corneal epithelial cell lines compared to the control samples."

Journal • Preclinical

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Apr 2023 ➔ Sep 2023

Trial completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA

TOPICAL NSAID INDUCED CORNEAL MELT: A CASE REPORT (ESCRS-WM 2023) - "She was commenced on topical Maxitrol (dexamethasone, polymyxin B sulphate, neomycin sulphate) and Acular (Ketorolac) QDS post-operatively. This case highlights the importance of awareness of the major side effect of topical NSAIDs. It is essential to identify patient cohorts at risk pre-operatively to avoid adverse outcomes, particularly those with pre-existing ocular surface disease."

Clinical • Corneal Abrasion • Ophthalmology

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Aug 2022 ➔ Apr 2023 | Trial primary completion date: Aug 2022 ➔ Apr 2023

Biomarker • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA

Effect of preoperative eyedrops on cytokine concentrations in aqueous humor of patients undergoing femtosecond laser-assisted cataract surgery. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Preoperative fluorometholone instillation reduced IL-8, and ketorolac tromethamine instillation reduced IL-8 and PGE, in aqueous humor of patients undergoing femtosecond laser surgery, with the combination of both eyedrops being more effective than either alone."

Clinical • Journal • Cataract • Immunology • Inflammation • Oncology • Ophthalmology • CXCL8 • IL6 • TNFA

Role of Clapiks in Myopic Overcorrection Post LASIK and PRK (ASCRS-ASOA 2021) - "The extended wear contact lenses of low Dk value was changed on weekly basis .ResultsThe average spherical equivalent of the 8 patients at 1 week postop was +1.50 D with the use of Acular and the soft contact lens. The average postop spherical equivalent at 1 month postop was +0.75 D. The mean regression with the use of ketorolac was +0.50 D. No side effects or complications were noted with the use of ketorolacConclusionThe use of ketorolac and soft contact lenses appears to be safe and effective for reducing small amounts of hyperopia in the postop myopic LASIK and PRK patients. CLAPIKS may be used clinically to avoid additional surgery for overcorrection."

Drugs for allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

[VIRTUAL] Post-injection Anti-inflammatory Drops (ARVO 2021) - "Of the patients that used eye drops, 6 (19.4%) used artificial tears, 9 (29%) used acular, and 16 (51.6%) used pred forte. The study confirms that a significant number of patients undergoing anti-VEG-F injections in an office setting will develop mild to moderate discomfort the day of the injection. We recommend counseling the patient about possible discomfort and making topical drops including lubricating drops, nonsteroidal, and steroid drops available on a short term basis following injections. This will increase patient satisfaction and lessen the number of post-injection phone calls regarding mild to moderate discomfort."

Ophthalmology

[VIRTUAL] Prednisolone and ketorolac versus ketorolac alone or dropless prophylaxis of macular thickening in cataract surgery (ARVO 2021) - " Low-risk participants scheduled for cataract removal were randomized to 1 of 5 anti-inflammatory prophylactic regimens; combination of prednisolone- (Pred Forte 1%) and ketorolac (Acular 0.5%) eye drops with or without preoperative initiation (Pred+NSAID-Pre (control) and Pred+NSAID-Post), ketorolac monotherapy with or without preoperative initiation (NSAID-Pre and NSAID-Post) or subtenon depot of dexamethasone (Dropless). Combination of prednisolone and NSAID eye drops was not superior to NSAID monotherapy in preventing central macular thickening, but subtenon depot of dexamethasone was inefficient as a dropless approach. Initiating prophylactic treatment 3 days before surgery was not superior to initiation on the day of surgery. Adding prednisolone to NSAID eye drops resulted in higher IOP during treatment."

Cataract • Ophthalmology

Effects of omega 3 polyunsaturated fatty acids, antioxidants and/or non-steroidal inflammatory drugs in the brain of neonatal rats exposed to intermittent hypoxia. (PubMed, Int J Dev Neurosci) - "Newborn rats were exposed to brief hypoxia (12% O ) during hyperoxia (50% O ) from the first day of life (P0) until P14 during which they received daily oral supplementation with antioxidants, namely coenzyme Q10 (CoQ10) or glutathione nanoparticles (nGSH), n-3 PUFAs and/or topical ocular ketorolac. Neonatal IH during a critical time of brain development causes inflammation and oxidative injury. Loss of therapeutic benefits of n-3 PUFAs suggest its susceptibility to oxidation in neonatal IH and therefore indicate that co-administration with antioxidants may be necessary to sustain its efficacy."

Journal • Preclinical • CNS Disorders • Hematological Disorders • Immunology • Inflammation • Rheumatoid Arthritis • Vascular Neurology • CDKN1A

Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Topical ketorolac 0.5% three times a day could enhance and sustain the efficacy of intravitreal bevacizumab in the treatment of DME."

Clinical • Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders